As the COVID-19 crisis continues, how has the U.K.’s biotech ecosystem fared?
- How much cash runway do companies have?
- Will management teams secure their target levels of financing?
- Are U.K. biotechs taking advantage of new government support packages, including the Future Fund and the Coronavirus Job Retention Scheme?
Following the discussion, BioCentury and BIA convene a special panel of U.K biotech CEOs and investors to discuss the survey, and the outlook for company building in a COVID-19 world.
Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc
Steve Bates, CEO, UK BioIndustry Association
Charlotte Casebourne - CEO, Theolytics
Jolyon Martin - Head of Business Development and Co-Founder, PetMedix